Resveratrol treatment does not reduce arterial inflammation in males at risk of type 2 diabetes: a randomized crossover trial.

Resveratrol has shown promising anti-inflammatory effects in in vitro and animal studies. We aimed to investigate this effect on arterial inflammation in vivo. This was an additional analysis of a double-blind randomized crossover trial which included eight male subjects with decreased insulin sensitivity who underwent an Arterial Resveratrol failed to attenuate arterial or systemic inflammation as measured with ZIEL: Resveratrol hat in In-vitro- und Tierstudien vielversprechende anti-inflammatorische Effekte gezeigt. Unser Ziel war es, diese Wirkung auf die arterielle Entzündung in vivo zu untersuchen. Es handelte sich um eine zusätzliche Analyse einer randomisierten Doppelblind-Crossover-Studie, an der acht männliche Probanden mit verminderter Insulinsensitivität teilnahmen, die sich nach 34 Tagen Placebo- und Resveratrol-Behandlung (150 mg/Tag) einer Die arterielle Resveratrol konnte die mittels

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

Disclosures: Joachim E. Wildberger receives institutional grants from Agfa, Morstel, Belgium; Bayer Healthcare, Berlin, Germany; GE, Chicago, Illinois; Optimed, Ettlingen, Germany; Philips Healthcare, Best, the Netherlands; Siemens Healthineers, Forchheim, Germany, and personal fees from the speaker’s bureau of Bayer Healthcare, Berlin, Germany and Siemens Healthineers, Forchheim, Germany. Ellen Boswijk, Marlies de Ligt, Marie-Fleur J. Habets, Alma M.A. Mingels, Wouter D. van Marken Lichtenbelt, Felix M. Mottaghy, Patrick Schrauwen and Jan Bucerius, have no relationships with industry currently or within the last two years. Conflicts of interest: All authors declare that they have no conflict of interest regarding the research presented in this manuscript.